Posted by Michael Wonder on 21 Feb 2018
NICE nod for Gilead’s pan-genotypic hepatitis C therapy
21 February 2018 - Gilead’s pan-genotypic treatment for hepatitis C Vosevi has won the National Institute for Health and Care Excellence’s seal of approval for use on the NHS.
Vosevi (sofosbuvir/velpatasvir/voxilaprevir; SOF/VEL/VOX) was cleared by European regulators in July last year as the first and only single tablet regimen for patients with any genotype of chronic hepatitis C virus infection.
The therapy was authorised as a 12-week treatment regimen, for patients without cirrhosis or with compensated cirrhosis, on the back of clinical data showing high cure rates.
